Correlation between ALK+ non-small cell lung cancer targeted therapy and thrombosis: a systematic review and network meta-analysis.

ABSTRACT:

Objective

The main adjuvant therapies for anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer include ALK tyrosine kinase inhibitors (TKI) and chemotherapy. We aimed to compare differences in the incidence of thromboembolism (TE) among different treatment options.

Design

Using a systematic review and Bayesian network meta-analysis (NMA).

Data sources

We searched PubMed, Embase, Cochrane Library, ClinicalTrials.gov and Web of Science databases before 10 June 2023.

Eligibility criteria

We included published randomised controlled trials (RCT) involving comparisons of treatments between chemotherapy and ALK-TKI drugs.

Data extraction and synthesis

Assessed risk bias with Cochrane tool. Conducted NMA with GEMTC in R, we evaluate the model fit

SUBMITTER: Qi Y 

PROVIDER: S-EPMC11448140 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature